Search clinical trials for: Empagliflozin low dose bid

Total 1981 results

Oblato, Inc.

Recruiting

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

Astrocytoma | Glioblastoma Multiforme | Oligodendroglioma | High-grade Glioma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Reistone Biopharma Company Limited

Terminated

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Vitiligo

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, France, Israel, Mexico, South Africa
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Biocad

Terminated

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) (COVER)

COVID-19 | Coronavirus Infection

Russian Federation
Lexeo Therapeutics

Recruiting

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Friedreich Ataxia | Cardiomyopathy, Secondary

United States, Canada
University of Oxford

Completed

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

Chikungunya | Zika

Mexico
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

Dry Eye Syndrome

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome (pSS)

Korea, Republic of
University of Missouri-Columbia
National Center for Complementary and Integrative Health (NCCIH); Office of...

Completed

A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults

HIV Infections

South Africa
AsclepiX Therapeutics, Inc.

Active, not recruiting

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (DISCOVER)

Neovascular Age-related Macular Degeneration

United States
Emmecell

Active, not recruiting

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Endothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial Decompensation

United States
Oncocross Australia Pty Ltd.

Completed

A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514

Cancer Cachexia

Australia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Anhui Provincial Hospital

Recruiting

Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer

Safety Issues | Efficacy, Self

China
Frontera Therapeutics

Recruiting

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

China
Kangpu Biopharmaceuticals, Ltd.

Completed

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (Lupus)

SLE; Drug

United States
Hebrew University of Jerusalem
aMoon fund

Completed

Examining the Effectiveness of a Tablet Video Game on Mood and Cognition (THRIVE)

Depressive Symptoms | Mood Disturbance

Israel
Genocea Biosciences, Inc.

Completed

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

Streptococcus Pneumoniae

United States
Kolon TissueGene, Inc.

Not yet recruiting

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease

Degenerative Disc Disease
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
The University of Texas Health Science Center,...

Terminated

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

Recurrent C. Difficile Infection

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Diabetes Mellitus, Type 1

Austria, Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Pluristem Ltd.

Completed

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Intermittent Claudication | Peripheral Artery Disease

United States, Germany, Korea, Republic of, Israel
Azura Ophthalmics
Syneos Health; Cliantha Research

Completed

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Dry Eye | Meibomian Gland Dysfunction

Canada, Australia, New Zealand
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Biocad

Completed

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Healthy

Russian Federation
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Emory University
National Cancer Institute (NCI)

Terminated

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19)

Pneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) Pneumonia

United States
Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Lexicon Pharmaceuticals

Completed

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Rheumatoid Arthritis

United States, Bulgaria, Czech Republic, Hungary, Poland, Serbia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Beijing Northland Biotech. Co., Ltd.

Completed

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Acute Myocardial Infarction

China
MedImmune LLC

Completed

A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

Non-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)

United States, Puerto Rico
Dr. Falk Pharma GmbH

Completed

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Germany
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Cellular Biomedicine Group Ltd.
RenJi Hospital

Completed

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

Knee Osteoarthritis

China
Oryn Therapeutics, LLC

Withdrawn

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

COVID-19

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan

Search clinical trials for: Empagliflozin low dose bid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations